Axima-CFR MALDI TOF Mass Spectrometer

描述(申请人提供)：最近通过质谱学进行蛋白质序列分析的进展与大型蛋白质数据库的可获得性在糖尿病研究中创造了独特的机会。本申请申请资金用于购买基质辅助激光解吸电离飞行时间(MALDI TOF)质谱仪，用于美国国立卫生研究院资助的研究项目，该项目目前由Joslin糖尿病中心的9名研究人员进行。这些研究项目与1型和2型糖尿病相关，将在Joslin的5个研究部分进行。这些研究涉及糖尿病研究的多个领域，包括与1型糖尿病相关的自身免疫、胰岛素抵抗的机制、2型糖尿病、肥胖、代谢和血管并发症。所要求的具体仪器是由Kratos Analytical制造的AXIMA-CFR MALDI TOF。该系统的特点包括单同位素分辨率(&gt；10000 Fwhm)、质量精度&lt；10ppm、灵敏度&lt；10fmol/亩L，以及能够产生无缝后震源衰变的独特专利曲线场反射仪。这种质谱仪的主要应用将是识别与糖尿病及其血管并发症相关的蛋白质表达和翻译后修饰的变化。马萨诸塞大学使用AXIMA-CFR进行的初步研究表明，该仪器对于本赠款中所述的拟议用途非常有效。该仪器将由一个Proteomies核心实验室操作和维护，该实验室位于Joslin的研究实验室的中心。据估计，该仪器的使用率至少为90%，相当于参加这笔赠款的9名调查员每人每周大约4个小时。糖尿病研究尚未完全受益于当前质谱学技术提供的信息。为获得这笔赠款而聚集的研究人员拥有可用的专业知识和研究模型，以及明确的需求，可以利用质谱蛋白质分析来确定治疗糖尿病及其血管并发症的新机制和目标。

DESCRIPTION (provided by applicant): Recent advances in protein sequence analysis by mass spectroscopy combined with the availability of large protein databases have created unique opportunities in diabetes research. This application requests funds for the acquisition of a Matrix Assisted Laser Desorption Ionization Time-of Flight (MALDI TOF) mass spectrometer to be used for NIH-funded research projects that are currently underway by nine Investigators at the Joslin Diabetes Center. These research projects are relevant to both type 1 and type 2 diabetes, and will be carried out in 5 research sections at the Joslin. These studies address a number of areas of diabetes research, including autoimmunity related to type 1 diabetes, mechanisms of insulin resistance, type 2 diabetes, obesity, metabolism, and vascular complications. The specific instrument requested is the Axima-CFR MALDI TOF manufactured by Kratos Analytical. Features of this system include monoisotopic resolution (>10000 Fwhm), mass accuracy <10 ppm, sensitivity of <10 fmol/mu l, and a unique patented curve field reflectron that enables the generation of seamless post source decay. The primary applications for this mass spectrometer will be to identify changes in protein expression and post-translational modification relevant to diabetes and its vascular complications. Preliminary studies using the Axima-CFR at the University of Massachusetts have demonstrated that this instrument is highly effective for the proposed uses described in this grant. This instrument will be operated and maintained by a Proteomies Core Laboratory, centrally located among research laboratories at the Joslin. Usage of this instrument is estimated as at least 90%, corresponding to approximately 4 hours per week for each of the 9 investigators participating in this grant. Diabetes research has not yet fully benefited from the information available from current mass spectroscopic technologies. The Investigators assembled for this grant have the expertise and research models available, as well as the clear needs, to utilize mass spectroscopic protein analysis for the identification of novel mechanism and targets for the treatment of diabetes and it vascular complications.